Comparisons of mumps virus potency estimates obtained by 50% cell culture infective dose assay and plaque assay

Vaccine

Volumn 28, Issue 7, 2010, Pages 1887-1892

  Forcic, Dubravko ^a   Košutić Gulija, Tanja ^a   Šantak, Maja ^a   Jug, Renata ^a   Ivancic Jelecki, Jelena ^a   Markusic, Maja ^a   Mažuran, Renata ^a  

^a INSTITUTE OF IMMUNOLOGY   (Croatia)

Author keywords

Cytopathic effect; Mumps virus; Virus potency estimate

Indexed keywords

ANIMAL CELL; ARTICLE; CELL CULTURE INFECTIVE DOSE 50; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; MUMPS VIRUS; NONHUMAN; PRIORITY JOURNAL; VERO CELL; VIRUS CULTURE; VIRUS INFECTIVITY; VIRUS MORPHOLOGY; VIRUS PLAQUE; VIRUS STRAIN;

ANIMALS; CERCOPITHECUS AETHIOPS; MUMPS VIRUS; PLAQUE ASSAY; VERO CELLS;

EID: 75249083637     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.11.049     Document Type: Article

References (24)

1. Hierholzer J.C., and Kilington R.A. Virus isolation and quantification. In: Mahy B.W.J., and Kangro H.O. (Eds). Virology methods manual (1996), Academic Press, London 27-45
2. Davis B.D., Dulbecco R., Eisen H.N., Ginsberg H.S., Wood W.B., and McCarthy M. Microbiology (1973), Harper & Row, Publishers, Inc., Hagerstown
3. Cooper P. The plaque assay of animal viruses. Adv Virus Res 8 (1961) 319-378
4. Flanagan T.D., and Barron A.L. Plaque formation by mumps virus and inhibition by antiserum. Appl Microbiol 19 2 (1970) 360-366
5. Clements C.J., Milstien J.B., and Grabowsky M. Research on alternative measles vaccines: technical background and recommended format for reporting field trials, Document EPI/GEN/88. 12 (1988), World Health Organization, Geneva
6. Carbone K.M., and Wolinsky J.S. Mumps virus. In: Knipe D., and Howley P. (Eds). Fields virology (2001), Lippincott, Williams and Wilkins, Philadelphia 1381-1400
7. Jin L., Rima B., Brown D., Orvell C., Tecle T., Afzal M., et al. Proposal for genetic characterisation of wild-type mumps strains: preliminary standardisation of the nomenclature. Arch Virol 150 9 (2005) 1903-1909
8. Santos C.L., Ishida M.A., Foster P.G., Sallum M.A., Benega M.A., Borges D.B., et al. Detection of a new mumps virus genotype during parotitis epidemic of 2006-2007 in the state of São Paulo, Brazil. J Med Virol 80 2 (2008) 323-329
9. WHO Expert Committee on biological standardization. WHO Technical Report Series 858 (1995), World Health Organization, Geneva
10. National Institute for Biological Standards and Control. WHO Reference Reagent, 1st International Reference Reagent for Mumps Vaccine, NIBSC code 90/534, Instructions for use (Version 3.0, Dated 03/03/2008) (2008), National Institute for Biological Standards and Control, Potters Bar
11. WHO Expert Committee on biological standardization. WHO Technical Report Series 840 (1994), World Health organization, Geneva
12. European Directorate for the Quality of Medicines & HealthCare. European Pharmacopoeia. sixth ed., Suppl. 6.1. (2007), Council of Europe, Strasbourg
13. Ivancic J., Forcic D., Kosutic Gulija T., Zgorelec R., Repalust L., Baricevic M., et al. Genetic characterization of a mumps virus isolate during passaging in the amniotic cavity of embryonated chicken eggs. Virus Res 99 2 (2004) 121-129
14. Šantak M., Košutić-Gulija T., Tešović G., Ljubin-Sternak S., Gjenero-Margan I., Betica-Radić L., et al. Mumps virus strains isolated in Croatia in 1998 and 2005: genotyping and putative antigenic relatedness to vaccine strains. J Med Virol 78 5 (2006) 638-643
15. Ivancic-Jelecki J., Santak M., and Forcic D. Variability of hemagglutinin-neuraminidase and nucleocapsid protein of vaccine and wild-type mumps virus strains. Infect Genet Evol 8 5 (2008) 603-613
16. Rubin S.A., Afzal M.A., Powell C.L., Bentley M.L., Auda G.R., Taffs R.E., et al. The rat-based neurovirulence safety test for the assessment of mumps virus neurovirulence in humans: an international collaborative study. J Infect Dis 191 7 (2005) 1123-1128
17. World Health Organization. Live mumps virus vaccine. Manual of laboratory methods. Document WHO/VSQ/97.04 (1997), World Health Organization, Geneva pp. 83-6
18. Afzal M.A., Elliott G.D., Rima B.K., and Orvell C. Virus and host cell dependent variation in transcription of mumps virus genome. J Gen Virol 71 3 (1990) 615-619
19. Afzal M.A., Dussupt V., Minor P.D., Pipkin P.A., Fleck R., Hockley D.J., et al. Assessment of mumps virus growth on various continuous cell lines by virological, immunological, molecular and morphological investigations. J Virol Methods 126 1-2 (2005) 149-156
20. Knowles W.A., and Cohen B.J. Efficient isolation of mumps virus from a community outbreak using the marmoset lymphoblastoid cell line B95a. J Virol Methods 96 1 (2001) 93-96
21. Forsey T., Heath A.B., and Minor P.D. A European collaborative study to assess the proficiency of laboratory estimates of potency of live measles, mumps and rubella tri-valent vaccines. Biologicals 21 3 (1993) 239-249
22. Afzal M.A., Marsden S., Hull R.M., Pipkin P.A., Bentley M.L., and Minor P.D. Evaluation of the neurovirulence test for mumps vaccines. Biologicals 27 1 (1999) 43-49
23. Rubin S.A., Snoy P.J., Wright K.E., Brown E.G., Reeve P., Beeler J.A., et al. The mumps virus neurovirulence safety test in Rhesus monkeys: a comparison of mumps virus strains. J Infect Dis 180 2 (1999) 521-525
24. Rubin S.A., Pletnikov M., Taffs R., Snoy P.J., Kobasa D., Brown E.G., et al. Evaluation of a neonatal rat model for prediction of mumps virus neurovirulence in humans. J Virol 74 11 (2000) 5382-5384